Thymosin Beta 4 (TB500) 5mg is a synthetic variant of the naturally occurring 43-amino acid peptide responsible for regulating cellular actin monomer sequestration, cell migration, and tissue remodeling mechanisms in laboratory models. Supplied exclusively for in vitro and preclinical research applications, PX1 Research provides high-purity Thymosin Beta 4 verified via RP-HPLC and mass spectrometry to ensure precise, reproducible experimental conditions.
Thymosin Beta 4 (TB500) 5mg is a synthetic variant of the naturally occurring 43-amino acid peptide responsible for regulating cellular actin monomer sequestration, cell migration, and tissue remodeling mechanisms in laboratory models. Supplied exclusively for in vitro and preclinical research applications, PX1 Research provides high-purity Thymosin Beta 4 verified via RP-HPLC and mass spectrometry to ensure precise, reproducible experimental conditions.
Thymosin Beta 4 (TB-500) is a synthetically produced 43-amino acid peptide derived from the primary structure of endogenous thymosin β4, a polypeptide ubiquitously expressed in intracellular fluids and eukaryotic tissues. Possessing the chemical formula C212H350N56O78S and a molecular weight of approximately 4963.5 Da, this molecule functions primarily as an actin-monomer-binding protein. In cellular physiology models, it plays an essential role in regulating the dynamic equilibrium between globular actin (G-actin) and filamentous actin (F-actin).
The primary functional sequence of Thymosin Beta 4 contains the hexapeptide motif LKKTET (Leu-Lys-Lys-Thr-Glu-Thr), which acts as the core actin-binding domain. Researchers evaluating cellular motility, cytoskeleton remodeling, and cell survival pathways utilize thymosin beta 4 (tb500) 5mg to study how peptide interaction with G-actin prevents spontaneous polymerization into microfilaments. This unique structural architecture facilitates directional cell migration, modern angiogenesis models, and intracellular signaling events without altering basal cytoskeletal gene transcription.
In preclinical laboratory settings, the principal mechanism of Thymosin Beta 4 centers on its capacity to sequester G-actin monomers in a 1:1 stoichiometric complex. By binding to unpolymerized actin, the peptide maintains a pool of available monomeric units ready for rapid localized polymerization upon chemical signaling. This regulation is fundamental to lamellipodia formation, focal adhesion dynamics, and cell motility during experimental wound healing assays.
Furthermore, in vitro analyses reveal that Thymosin Beta 4 downregulates specific pro-inflammatory signaling pathways, including nuclear factor kappa B (NF-κB) transcription, while stimulating downstream phosphorylation of Akt (protein kinase B). Researchers studying actin sequestration mechanisms often investigate how this dual mechanism promotes survival in hypoxic endothelial cells, preserves cardiac progenitor cells in ischemic models, and drives cell proliferation in dermal fibroblastic lines.
Angiogenesis—the formation of new blood vessels from pre-existing microvasculature—is a primary area of focus in Thymosin Beta 4 preclinical literature. In vitro tube formation assays using human umbilical vein endothelial cells (HUVECs) demonstrate that exposure to purified TB-500 accelerates capillary-like tube structure formation. This response is mediated via upregulation of vascular endothelial growth factor (VEGF) expressions and matrix metalloproteinase (MMP) secretion.
Rodent models of tissue ischemia have further corroborated these cellular findings. When administered in controlled laboratory settings, TB-500 enhances local capillary density and blood flow restoration to injured tissues. Researchers studying microvascular regeneration utilize the 5mg vial format to establish standardized dosage concentration curves across multi-well assays and tissue explant cultures, documenting accelerated migration of endothelial cells across synthesized extracellular matrices.
Within tissue repair and cellular migration research, multiple peptide targets are routinely analyzed side-by-side to delineate distinct metabolic and signaling pathways. While thymosin beta 4 (tb500) 5mg functions via direct G-actin binding and cytoskeleton reorganization, alternative peptides execute repair signals through independent pathways.
For instance, BPC-157 5mg operates largely through the VEGFR2 pathway, nitric oxide synthesis, and focal adhesion kinase (FAK) activation, establishing a complementary cascade for tendon, ligament, and gastrointestinal endothelial models. Meanwhile, GHK-Cu 50mg functions primarily as a copper-binding peptide that modulates collagen synthesis, gene expression of extracellular matrix enzymes, and antioxidant pathways. For anti-inflammatory focus, researchers also evaluate tripeptide analogs such as KPV 10mg alongside TB-500. Detailed breakdowns comparing these compounds are available in our technical synthesis on TB-500 vs BPC-157 mechanisms.
Beyond structural actin sequestration, preclinical models highlight Thymosin Beta 4's ability to modulate acute and chronic inflammatory responses. In vitro rodent cardiac injury models indicate that TB-500 attenuates myocyte apoptosis following ischemia-reperfusion stress. The peptide appears to recruit cardiac progenitor cells to damaged epicardial tissue, upregulating survival kinases such as Integrin-Linked Kinase (ILK) and Akt.
Additionally, cell culture studies evaluating inflammatory mediator suppression demonstrate reduced expression of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6. By blunting excessive macrophage infiltration and suppressing ROS-mediated oxidative stress in vitro, researchers utilize TB-500 to explore therapeutic windows for fibrotic tissue attenuation and organ preservation strategies.
To ensure precise analytical measurements and maintain chemical integrity, appropriate reconstitution practices must be maintained in the laboratory. Thymosin Beta 4 (TB500) 5mg is supplied as a lyophilized (freeze-dried) sterile powder. Lyophilization preserves the peptide matrix, preventing premature hydrolysis or oxidation during ambient transit.
For laboratory preparation, investigators should reconstitute the 5mg vial using standard sterile Bacteriostatic Water (containing 0.9% benzyl alcohol) or sterile 0.9% Sodium Chloride injection solution. The diluent should be introduced down the side of the glass vial to prevent turbulent agitation, followed by gentle swirling until complete dissolution is achieved. Vortexing should be strictly avoided to prevent physical denaturation of the secondary structure. Reconstituted aliquots should be used immediately or stored under refrigeration (2°C to 8°C) for short-term assays, or frozen (-20°C to -80°C) for extended research cycles.
Assay reproducibility relies entirely on compound purity and batch consistency. PX1 Research mandates rigorous third-party testing protocols for every lot of thymosin beta 4 (tb500) 5mg. Quantitative verification involves Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to establish peptide purity metrics, ensuring values consistently meet or exceed 99.0%.
Electrospray Ionization Mass Spectrometry (ESI-MS) is simultaneously performed to verify exact molecular weight and confirm the sequence identity of the synthesized polypeptide against reference standards. Analytical documentation, including chromatograms and spectrum peak analyses, is cataloged on our research library hub and linked directly to individual product lots.
Bacterial endotoxins (lipopolysaccharides) represent a critical confounding variable in cell culture and tissue model assays, capable of inducing non-specific inflammatory signaling and cell death. To ensure experimental control, all PX1 Research peptides undergo quantitative Chromogenic Limulus Amebocyte Lysate (LAL) testing to guarantee endotoxin levels remain below standard analytical thresholds (<0.01 EU/mg).
Our analytical testing is conducted exclusively through independent, ISO 17025 accredited testing laboratories. Facilities manufacturing compounds for PX1 Research operate under strict cGMP-compliant guidelines within the United States, providing complete lot traceability from raw amino acid coupling through final lyophilization.
Procuring high-grade reagents requires complete transparency regarding country of origin, synthesis methodology, and analytical validation. PX1 Research simplifies institutional procurement by providing verified USA-manufactured research peptides tailored for academic, biotech, and pharmaceutical laboratories. Principal investigators and laboratory buyers managing multi-project budgets can access volume pricing through our wholesale laboratory account portal.
All orders ship directly from centralized logistics centers located in California and Arizona. Standard operating procedures dictate same-day fulfillment for orders processed Monday through Friday, ensuring rapid delivery and minimized exposure to environmental temperature fluctuations during transit.
What is the recommended storage temperature for lyophilized Thymosin Beta 4 5mg?
Lyophilized (freeze-dried) Thymosin Beta 4 should be stored at -20°C upon receipt for long-term stability. For short-term laboratory storage (less than 30 days), desiccated vials may be kept under standard refrigeration between 2°C and 8°C, protected from direct light exposure.
How should Thymosin Beta 4 5mg be reconstituted for in vitro assays?
Reconstitute the 5mg lyophilized powder using sterile Bacteriostatic Water or sterile 0.9% Sodium Chloride solution. Slowly add the solvent along the inner wall of the vial and gently rotate until fully dissolved. Avoid vigorous shaking or high-speed vortexing to preserve peptide structural integrity.
What is the purity specification for PX1 Research TB-500?
PX1 Research guarantees a minimum purity threshold of ≥99.0% for all Thymosin Beta 4 (TB500) 5mg lots. Each batch is validated via third-party RP-HPLC and ESI-MS analysis.
Does PX1 Research provide Certificate of Analysis (COA) documentation?
Yes. Every single batch of Thymosin Beta 4 is accompanied by a publicly accessible, lot-specific Certificate of Analysis detailing HPLC purity curves, mass spectral identity, and endotoxin assay results.
What is the primary cellular target of Thymosin Beta 4 in preclinical studies?
The primary molecular target of Thymosin Beta 4 is globular actin (G-actin). It forms a 1:1 complex to sequester monomeric actin, regulating filament assembly, cell migration, focal adhesion, and endothelial tube formation.
How does TB-500 differ from BPC-157 in research applications?
While both peptides are studied in cell migration and repair models, TB-500 works via G-actin sequestration and direct cytoskeletal restructuring. In contrast, BPC-157 acts primarily via VEGFR2 pathway stimulation, nitric oxide production, and FAK activation.
Is Thymosin Beta 4 (TB500) approved for human consumption or therapeutic use?
No. Thymosin Beta 4 (TB500) 5mg provided by PX1 Research is strictly designated for laboratory research, in vitro studies, and preclinical experimental applications. It is not for human, clinical, or veterinary use.
What are the endotoxin limits on PX1 Research peptides?
PX1 Research enforces strict endotoxin control standards, testing all batches via chromogenic LAL assays to confirm levels remain under <0.05 EU/mg (and typically <0.01 EU/mg), eliminating confounding inflammatory variables in cell cultures.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.